Jan P. M. Hendriks
Directeur Général chez InnoCore Technologies BV
Profil
Jan P.
M.
Hendriks has founded InGell Labs BV in 2010, where he holds the title of Chief Executive Officer.
Currently, he is the Chief Executive Officer & Director at InnoCore Technologies BV and an Investment Manager at Pharma Connect Capital since 2017.
Previously, he was the Chief Executive Officer at Pharma Bio-Research Group BV.
Postes actifs de Jan P. M. Hendriks
| Sociétés | Poste | Début |
|---|---|---|
InnoCore Technologies BV
 InnoCore Technologies BV Pharmaceuticals: MajorHealth Technology InnoCore Technologies BV develops drug delivery technologies. It serves the pharmaceutical and medical device industry by developing and manufacturing innovative drug delivery systems that enhance their products. The company was founded by Theodorus Adrianus Cornelius Flipsen and Rob Steendam in 2004 and is headquartered in Groningen, the Netherlands. | Directeur Général | - |
InGell Labs BV
 InGell Labs BV Pharmaceuticals: MajorHealth Technology InGell Labs BV develops polymer-based injectable hydrogels for drug delivery. The firm’s products include InGell LQP, Ingell Gamma, and running in-house projects. It offers its bioabsorbable injectable hydrogel systems for reducing side-effects and localization of novel therapies to life-cycle management opportunities. The company was founded by Paul van Midwoud, Theodorus Adrianus Cornelius Flipsen, Mike G. de Leeuw, and Jan P. M. Hendriks in 2010 and is headquartered in Groningen, the Netherlands. | Directeur Général | 01/01/2010 |
Pharma Connect Capital
 Pharma Connect Capital Investment ManagersFinance Pharma Connect Capital BV is a private equity firm with headquarters in Groningen, the Netherlands. It was founded in 2017. | Private Equity Investor | 20/10/2017 |
Anciens postes connus de Jan P. M. Hendriks
| Sociétés | Poste | Fin |
|---|---|---|
Pharma Bio-Research Group BV
 Pharma Bio-Research Group BV Miscellaneous Commercial ServicesCommercial Services Pharma Bio-Research Group BV specialized in research in the pharmaceutical and biotech sector. It offered services for phase I/IIA clinical research, bioanalysis and biometrics. Founded in 1981, the company was headquartered in Zuidlaren, the Netherlands | President | 01/07/2006 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Pharma Bio-Research Group BV
Pharma Bio-Research Group BV Miscellaneous Commercial ServicesCommercial Services Pharma Bio-Research Group BV specialized in research in the pharmaceutical and biotech sector. It offered services for phase I/IIA clinical research, bioanalysis and biometrics. Founded in 1981, the company was headquartered in Zuidlaren, the Netherlands | Commercial Services |
InnoCore Technologies BV
InnoCore Technologies BV Pharmaceuticals: MajorHealth Technology InnoCore Technologies BV develops drug delivery technologies. It serves the pharmaceutical and medical device industry by developing and manufacturing innovative drug delivery systems that enhance their products. The company was founded by Theodorus Adrianus Cornelius Flipsen and Rob Steendam in 2004 and is headquartered in Groningen, the Netherlands. | Health Technology |
InGell Labs BV
InGell Labs BV Pharmaceuticals: MajorHealth Technology InGell Labs BV develops polymer-based injectable hydrogels for drug delivery. The firm’s products include InGell LQP, Ingell Gamma, and running in-house projects. It offers its bioabsorbable injectable hydrogel systems for reducing side-effects and localization of novel therapies to life-cycle management opportunities. The company was founded by Paul van Midwoud, Theodorus Adrianus Cornelius Flipsen, Mike G. de Leeuw, and Jan P. M. Hendriks in 2010 and is headquartered in Groningen, the Netherlands. | Health Technology |
Pharma Connect Capital
Pharma Connect Capital Investment ManagersFinance Pharma Connect Capital BV is a private equity firm with headquarters in Groningen, the Netherlands. It was founded in 2017. | Finance |
